Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Dow
Express Scripts
Johnson and Johnson
AstraZeneca
Medtronic

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Pembrolizumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Pembrolizumab: Patents, clinical trial progress, indications

Pembrolizumab is an investigational drug.

There have been 863 clinical trials for Pembrolizumab. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2019.

The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Carcinoma, and Lung Neoplasms. The leading clinical trial sponsors are Merck Sharp & Dohme Corp., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are seventy-four US patents protecting this investigational drug and one international patent.

Recent Clinical Trials for Pembrolizumab
TitleSponsorPhase
Neo-adjuvant Pembrolizumab and Radiotherapy in Localised MSS Rectal CancerUniversity Hospital, GenevaPhase 2
TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast CancerMerck Sharp & Dohme Corp.Phase 2
TAC Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy and L-NMMA in Triple Negative Breast CancerThe Methodist Hospital SystemPhase 2

See all Pembrolizumab clinical trials

Clinical Trial Summary for Pembrolizumab

Top disease conditions for Pembrolizumab
Top clinical trial sponsors for Pembrolizumab

See all Pembrolizumab clinical trials

US Patents for Pembrolizumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Pembrolizumab   Start Trial Methods for the treatment of Kaposi's sarcoma or KSHV-induced lymphoma using immunomodulatory compounds, and uses of biomarkers Celgene Corporation (Summit, NJ) The United States of America, as Represented by the Secretary, Department of Health and Human Services (Washington, DC)   Start Trial
Pembrolizumab   Start Trial Antibody-drug conjugates and immunotoxins Oncomatryx Biopharma, S.L. (Derio, ES)   Start Trial
Pembrolizumab   Start Trial Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof KANGPU BIOPHARMACEUTICALS, LTD. (Shanghai, CN)   Start Trial
Pembrolizumab   Start Trial Methods of treatment with antagonists against PD-1 and PD-L1 in combination with radiation therapy MedImmune Limited (Cambridge, GB)   Start Trial
Pembrolizumab   Start Trial Process for preparing an anti-cancer agent, 1-((4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-6-methoxyquinolin-7-yloxy)meth- yl)cyclopropanamine, its crystalline form and its salts Advenchen Pharmaceuticals, LLC (Moorpark, CA)   Start Trial
Pembrolizumab   Start Trial Immunoregulatory agents Flexus Biosciences, Inc. (Princeton, NJ)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Pembrolizumab

Drugname Country Document Number Estimated Expiration Related US Patent
Pembrolizumab European Patent Office 3313818 2035-06-26   Start Trial
Pembrolizumab Japan 2018527302 2035-06-26   Start Trial
Pembrolizumab World Intellectual Property Organization (WIPO) 2016210262 2035-06-26   Start Trial
Pembrolizumab Canada 2937600 2034-02-06   Start Trial
Pembrolizumab China 105980411 2034-02-06   Start Trial
Pembrolizumab Denmark 3102606 2034-02-06   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
McKinsey
Merck
Moodys
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.